Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:approvalYear |
2021
|
| gptkbp:CEO |
gptkb:Rachelle_Jacques
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
regenerative medicine
rare diseases |
| gptkbp:foundedYear |
2016
|
| gptkbp:headquartersLocation |
gptkb:Durham,_North_Carolina
|
| https://www.w3.org/2000/01/rdf-schema#label |
Enzyvant Sciences
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:mergedInto |
gptkb:Altavant_Sciences
|
| gptkbp:notableAchievement |
first FDA-approved thymus tissue product
|
| gptkbp:parentCompany |
gptkb:Sumitomo_Pharma
gptkb:Roivant_Sciences |
| gptkbp:product |
gptkb:Rethymic
RYZUMVI |
| gptkbp:receivedFDAApprovalFor |
gptkb:Rethymic
|
| gptkbp:specializesIn |
cell and gene therapies
|
| gptkbp:website |
https://www.enzyvant.com/
|
| gptkbp:bfsParent |
gptkb:Roivant_Sciences
|
| gptkbp:bfsLayer |
5
|